
FDA Approves Biosimilars for Cancer-Related Skeletal Events
The Food and Drug Administration (FDA) has approved Stoboclo (CT-P41, denosumab-bmwo) and Osenvelt (CT-P41, denosumab-bmwo), biosimilars referencing Prolia (denosumab) and Xgeva (denosumab), to protect bone health in patients undergoing cancer treatment. …